Doctors in Canada can now request psychedelic-assisted therapies for their patients through a new program, following an amendment to Health Canada’s Special Access Program (SAP).
Technology Networks spoke to the co-founder of Field Trip Health, a Toronto-based provider of ketamine therapy, on why 2021 was such a significant year for psychedelics.
The company behind the trial has expanded it to include three other behavioral addictions: binge eating disorder, compulsive sexual behavior and internet gaming disorder.
To date, no classical psychedelic agents have been approved for use as a medicine but what does convention tell us about the way these drugs will be scrutinized and assessed for quality?
Stephen Wright reviews the status of pre-clinical and clinical research into the use of LSD to treat a range of conditions and provide insights into the future of research involving this drug.
The researchers came to their conclusion after providing the drug to participants of a controlled trial of psilocybin-mediated therapy.
The year posed many challenges, but cannabis businesses, research centers, and reform groups still managed to make impressive headway. Analytical Cannabis looks back on the stories and issues that dominated the cannabis industry in 2021.
Participants in ayahuasca ceremonies report reductions in stress, anxiety, and depression whether they are given ayahuasca or not, a placebo-controlled study from researchers at Maastricht University has found.
These epigenetic changes may help to explain the long-lasting improvements to mental health identified in other recent psychedelic research projects.